FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W102612906> ?p ?o ?g. }

• W102612906 abstract "Background: The use of drug eluting stents (DES) has improved clinical and angiographic outcomes by reducing the need for target vessel revascularization (TVR). Clinical outcomes associated with the use a novel DES, the Zotarolimus-eluting phosphorylcholine-coated (Endeavor®) stent are less well established. A randomized clinical trial examining the benefits of the Endeavor® stent the rates of target vessel revascularization (TVR), target lesion revascularization (TLR) and stent thrombosis (ST) rates at 9 months in a select “study population” were reported as 7.9%, 4.6% and 0.5% respectively. These studies examined the outcomes of the Endeavor® stents in patients with single and non-complex lesions, while excluding patients with Acute Coronary Syndrome (ACS), Left Main (LM) lesions or In-stent restenosis (ISR). The outcomes of the Endeavor® stents in a “real-world” population have not been studied. The objective of this study was to evaluate the safety and efficacy of Endeavor® stents in consecutive patients from a single, high volume Canadian center. Methods & Results: The charts and angiogram reports of consecutive pts between June 2005 and June 2006, who received ≥ 1 Endeavor® stents were reviewed (n=462). In total, 667 Endeavor® stents were deployed in 462 patients. These patients were: 71% male, 65+/−9.1 year-old, 45% DM, 51% smokers, 62% HTN, 73% with dyslipidemia, and 5% with previous bypass surgery. The indications for stenting were: stable CAD 47.7%, ACS 47.1% and STEMI 5.1%. Endeavor® stents were utilized for ISR in 9% of cases. Average stent size was 19.7 +/− 5.8 × 2.9 +/− 0.3mm. At 12 month follow-up, TLR and TVR rates of 6.9% and 8.9% were observed, along with 2 cases of acute ST. There were no cases of late ST (>1 month post stent implantation). Myocardial Infarction occurred in 3.5% patients over 12 months. Discussion: In a Canadian interventional cardiology center, TLR, TVR and ST rates of 6.9%, 8.9% and 0.6% were observed at 12 months post-implantation. Despite including patients with multiple lesions, complex lesions, ACS and ISR, the rates observed at our center were comparable to those observed in a select study population. Most importantly there were no late stent thrombosis." @default.
• W102612906 created "2016-06-24" @default.
• W102612906 creator A5004831482 @default.
• W102612906 creator A5046920499 @default.
• W102612906 creator A5057283948 @default.
• W102612906 creator A5085007326 @default.
• W102612906 date "2007-10-16" @default.
• W102612906 modified "2023-09-27" @default.
• W102612906 title "Abstract 2155: One year clinical outcomes associated with the use of a Zotarolimus eluting stent: A Single-Center Canadian Experience" @default.
• W102612906 doi "https://doi.org/10.1161/circ.116.suppl_16.ii_467-b" @default.
• W102612906 hasPublicationYear "2007" @default.
• W102612906 type Work @default.
• W102612906 sameAs 102612906 @default.
• W102612906 citedByCount "0" @default.
• W102612906 crossrefType "journal-article" @default.
• W102612906 hasAuthorship W102612906A5004831482 @default.
• W102612906 hasAuthorship W102612906A5046920499 @default.
• W102612906 hasAuthorship W102612906A5057283948 @default.
• W102612906 hasAuthorship W102612906A5085007326 @default.
• W102612906 hasConcept C126322002 @default.
• W102612906 hasConcept C126838900 @default.
• W102612906 hasConcept C141071460 @default.
• W102612906 hasConcept C2777546689 @default.
• W102612906 hasConcept C2777698277 @default.
• W102612906 hasConcept C2778283817 @default.
• W102612906 hasConcept C2778583881 @default.
• W102612906 hasConcept C2779464278 @default.
• W102612906 hasConcept C2780073493 @default.
• W102612906 hasConcept C2780400711 @default.
• W102612906 hasConcept C2780797203 @default.
• W102612906 hasConcept C2781464078 @default.
• W102612906 hasConcept C2908647359 @default.
• W102612906 hasConcept C500558357 @default.
• W102612906 hasConcept C71924100 @default.
• W102612906 hasConcept C99454951 @default.
• W102612906 hasConceptScore W102612906C126322002 @default.
• W102612906 hasConceptScore W102612906C126838900 @default.
• W102612906 hasConceptScore W102612906C141071460 @default.
• W102612906 hasConceptScore W102612906C2777546689 @default.
• W102612906 hasConceptScore W102612906C2777698277 @default.
• W102612906 hasConceptScore W102612906C2778283817 @default.
• W102612906 hasConceptScore W102612906C2778583881 @default.
• W102612906 hasConceptScore W102612906C2779464278 @default.
• W102612906 hasConceptScore W102612906C2780073493 @default.
• W102612906 hasConceptScore W102612906C2780400711 @default.
• W102612906 hasConceptScore W102612906C2780797203 @default.
• W102612906 hasConceptScore W102612906C2781464078 @default.
• W102612906 hasConceptScore W102612906C2908647359 @default.
• W102612906 hasConceptScore W102612906C500558357 @default.
• W102612906 hasConceptScore W102612906C71924100 @default.
• W102612906 hasConceptScore W102612906C99454951 @default.
• W102612906 hasIssue "suppl_16" @default.
• W102612906 hasLocation W1026129061 @default.
• W102612906 hasOpenAccess W102612906 @default.
• W102612906 hasPrimaryLocation W1026129061 @default.
• W102612906 hasRelatedWork W1582820201 @default.
• W102612906 hasRelatedWork W1985739550 @default.
• W102612906 hasRelatedWork W2037153424 @default.
• W102612906 hasRelatedWork W2057591003 @default.
• W102612906 hasRelatedWork W2151857625 @default.
• W102612906 hasRelatedWork W2157330827 @default.
• W102612906 hasRelatedWork W2414576070 @default.
• W102612906 hasRelatedWork W2418309334 @default.
• W102612906 hasRelatedWork W2548677575 @default.
• W102612906 hasRelatedWork W2735498768 @default.
• W102612906 hasVolume "116" @default.
• W102612906 isParatext "false" @default.
• W102612906 isRetracted "false" @default.
• W102612906 magId "102612906" @default.
• W102612906 workType "article" @default.